Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkAssessment of Long-Term Distant Recurrence-Free Survival Associated with Tamoxifen Therapy in Postmenopausal Patients with Luminal A or Luminal B Breast Cancer

The Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990 included 462 postmenopausal patients with lymph node-negative breast cancer. This secondary analysis of trial data (including a 2014 tumor tissue assessment with immunohistochemistry and Agilent microarrays) looked for long-term survival benefit with tamoxifen. The authors conclude that patients with luminal A tumor subtype appeared to have a long-term (i.e., 15-year) benefit from tamoxifen therapy, and patients with luminal B subtype appeared to have an early benefit (i.e., 5 years) from therapy, when the risk of distant metastatic disease was high.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form